Edited by James Chalmers and Stefano Aliberti
Volume 13 Supplement 1
Bronchiectasis: still an orphan disease?
Publication of this supplement was funded by Novamedia and Italian Respiratory Society (IRS). The articles have undergone the journal's standard peer review process for supplements. SA is an associate editor of Multidisciplinary Respiratory Medicine, also a speaker or on advisory boards on bronchiectasis, non-tuberculous mycobacteria and low respiratory tract infection for the following: Bayer, Insmed, Cheiesi, Menarini, Mundipharma, GlaxoSmithKline, AstraZeneca, Grifols, Guidotti, Malesci, Zambon, Quinsair, Actavis, Novartis, BI, Raptor, Horizon Pharma. JC has recevied research grants from Aradigm Corporation, Bayer Healthcare, Grifols, AstraZeneca, GlaxoSmithKline and Boehringer-Ingelheim. JC also received consulting fees from Aradigm Corporation, Bayer Healthcare, Grifols, GlaxoSmithKline, Boehringer Ingelheim, Chiesi, Pfizer and Napp.
Milan, Italy06-08 July 2017
Official journal of
The official journal of the Italian Respiratory Society - Società Italiana di Pneumologia (IRS/SIP)
Annual Journal Metrics
55 days to first decision for reviewed manuscripts only
48 days to first decision for all manuscripts
86 days from submission to acceptance
47 days from acceptance to publication
1.139 - Source Normalized Impact per Paper (SNIP)
0.698 - SCImago Journal Rank (SJR)
2.21 - CiteScore
192 Altmetric mentions